These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19925410)

  • 1. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization.
    Tolentino MJ
    Curr Mol Med; 2009 Nov; 9(8):973-81. PubMed ID: 19925410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
    Andreoli CM; Miller JW
    Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin-1-Based Antiangiogenic Therapy.
    Sims JN; Lawler J
    J Ocul Pharmacol Ther; 2015 Sep; 31(7):366-70. PubMed ID: 26352160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
    Ng EW; Shima DT; Calias P; Cunningham ET; Guyer DR; Adamis AP
    Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineovascular agents in the treatment of eye diseases.
    Eichler W; Yafai Y; Wiedemann P; Fengler D
    Curr Pharm Des; 2006; 12(21):2645-60. PubMed ID: 16842164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies for the treatment of wet age-related macular degeneration--VEGF Trap-Eye.
    Rejdak R; Szkaradek M; Grieb P; Jünemann AG
    Klin Oczna; 2011; 113(10-12):376-8. PubMed ID: 22384659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
    Eyetech Study Group
    Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-17: The Role for Pathological Angiogenesis in Ocular Neovascular Diseases.
    Li Y; Zhou Y
    Tohoku J Exp Med; 2019 Feb; 247(2):87-98. PubMed ID: 30773517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor biology: clinical implications for ocular treatments.
    Bhisitkul RB
    Br J Ophthalmol; 2006 Dec; 90(12):1542-7. PubMed ID: 17114590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising new treatments for neovascular age-related macular degeneration.
    Michels S; Schmidt-Erfurth U; Rosenfeld PJ
    Expert Opin Investig Drugs; 2006 Jul; 15(7):779-93. PubMed ID: 16787141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects.
    van der Giet M; Henkel C; Schuchardt M; Tolle M
    Curr Pharm Des; 2015; 21(24):3548-56. PubMed ID: 25714990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development.
    Amadio M; Govoni S; Pascale A
    Pharmacol Res; 2016 Jan; 103():253-69. PubMed ID: 26678602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition.
    Lin KL; Hirose T; Kroll AJ; Lou PL; Ryan EA
    Semin Ophthalmol; 2009; 24(2):70-6. PubMed ID: 19373689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Angiogenesis and antiangiogenesis in intraocular tumors].
    Macovei L
    Oftalmologia; 2010; 54(4):24-6. PubMed ID: 21516858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A brief history of anti-VEGF for the treatment of ocular angiogenesis.
    Kim LA; D'Amore PA
    Am J Pathol; 2012 Aug; 181(2):376-9. PubMed ID: 22749677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye.
    Sene A; Chin-Yee D; Apte RS
    Trends Mol Med; 2015 Jan; 21(1):43-51. PubMed ID: 25457617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of retinal diseases with VEGF antagonists.
    Schlingemann RO; Witmer AN
    Prog Brain Res; 2009; 175():253-67. PubMed ID: 19660661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.